This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Epileptic seizures in children

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Epilepsy is defined as the tendency to continuing seizures.

Epilepsy is the commonest paediatric neurological problem. Estimates suggest that 0.7-0.8% of school-aged children have active epilepsy (1).

60% of adult patients with epilepsy had their first fit during childhood.

Note that it is recommended that all children who have had a first non-febrile seizure should be seen as soon as possible by a specialist in the management of the epilepsies to ensure precise and early diagnosis and initiation of therapy as appropriate to their needs (2,3).

When possible, choose which anti-epileptic drug (AED) to offer on the basis of the presenting epilepsy syndrome. If the epilepsy syndrome is not clear at presentation, base the decision on the presenting seizure type(s) (3).

A large multicentre trial (the SANAD trial) evaluating newer drugs in newly diagnosed epilepsy (accepting some limitations) suggested that sodium valproate should be the drug of choice in generalised and unclassifiable epilepsies, and lamotrigine in focal epilepsies (3).

Reference:

  1. 1) Appleton R, Gibbs J (Eds). Epilepsy in Childhood and Adolescence. Second edition. London: Martin Dunitz Ltd, 1998.
  2. NICE (April 2004). Newer drugs for epilepsy in children.
  3. NICE (April 2018). Epilepsies: diagnosis and management

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.